Live Analyst Rating Changes 1506 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Michael Matson
NDM
Michael Matson
Needham
Wall Street Analyst
★★☆☆☆
#1891
on 13Foresight · ranked by our own returns
50%
Success Rate
+14.7%
Average Return
18 of 36 calls profitable · +7.9% vs benchmark
📈 Across the calls we could measure, roughly 50% of Michael Matson's ratings turned a profit when each position was held for 1 year — averaging +14.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

140 Buy 68 Hold 0 Sell
Michael's Stock Coverage 34 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
MDT
Medtronic
 Jun 17, 2026 BUY Buy
+24.9% avg upside
38 analysts
$101.00
29.26% Upside
 +1.5%
TMDX
TransMedics Group
 Jun 09, 2026 BUY Strong Buy
+57.4% avg upside
15 analysts
$142.00
93.97% Upside
 -0.9%
VCYT
Veracyte
 Jun 01, 2026 BUY Strong Buy
-18.0% avg upside
17 analysts
$57.00
11.14% Upside
 ·
ICUI
ICU Medical
 May 27, 2026 BUY Strong Buy
+16.0% avg upside
9 analysts
$165.00
19.67% Upside
 ·
BSX
Boston Scientific
 May 18, 2026 BUY Strong Buy
+73.9% avg upside
38 analysts
$77.00
71.26% Upside
 -19.0%
ENOV
Enovis
 May 18, 2026 BUY Strong Buy
+230.7% avg upside
37 analysts
$52.00
149.49% Upside
 -1.4%
RMD
Resmed
 May 15, 2026 HOLD Buy
+26.6% avg upside
27 analysts
 — -4.3%
LUCD
Lucid Diagnostics
 May 14, 2026 BUY Strong Buy
+378.3% avg upside
8 analysts
$3.00
205.26% Upside
 +0.5%
IMDX
Insight Molecular Diagnostics
 May 14, 2026 BUY Buy
+1.1% avg upside
10 analysts
$9.00
69.11% Upside
 ·
STE
Steris
 May 12, 2026 HOLD Strong Buy
+23.6% avg upside
10 analysts
 — -1.3%
AORT
Artivion
 May 08, 2026 BUY Strong Buy
+91.7% avg upside
8 analysts
$44.00
107.63% Upside
 -20.0%
PSNL
Personalis
 May 08, 2026 BUY Strong Buy
+19.1% avg upside
11 analysts
$12.00
23.03% Upside
 +63.7%
INGN
Inogen
 May 08, 2026 BUY Buy
+287.2% avg upside
7 analysts
$12.00
88.46% Upside
 -9.0%
TFX
Teleflex
 May 07, 2026 BUY Buy
+44.0% avg upside
19 analysts
$147.00
17.55% Upside
 -3.3%
HAE
Haemonetics
 May 07, 2026 HOLD Buy
-8.0% avg upside
17 analysts
 — +7.6%
ESTA
Establishment Labs Holdings
 May 06, 2026 BUY Strong Buy
+0.0% avg upside
12 analysts
$86.00
4.32% Upside
 +10.8%
ATRC
Atricure
 May 06, 2026 BUY Strong Buy
+66.4% avg upside
12 analysts
$45.00
65.93% Upside
 +0.4%
LIVN
LivaNova
 May 06, 2026 BUY Strong Buy
-0.0% avg upside
14 analysts
$81.00
3.24% Upside
 +5.6%
INMD
InMode
 May 06, 2026 HOLD Buy
+42.2% avg upside
9 analysts
 — -1.7%
MMSI
Merit Medical Systems
 May 01, 2026 BUY Strong Buy
+38.7% avg upside
15 analysts
$90.00
37.98% Upside
 +0.9%
KIDS
OrthoPediatrics
 May 01, 2026 BUY Strong Buy
+64.3% avg upside
10 analysts
$30.00
65.18% Upside
 +14.0%
SYK
Stryker
 May 01, 2026 BUY Strong Buy
+25.2% avg upside
36 analysts
$418.00
38.82% Upside
 +3.0%
CNMD
Conmed
 Apr 30, 2026 HOLD Hold
+82.8% avg upside
12 analysts
$35.96
11.90% Upside
 -0.9%
NEO
NeoGenomics
 Apr 29, 2026 BUY Strong Buy
+46.6% avg upside
17 analysts
$15.00
44.43% Upside
 +24.4%
ZBH
Zimmer Biomet Holdings
 Apr 28, 2026 HOLD Buy
+28.0% avg upside
37 analysts
 — +7.2%
PEN
Penumbra
 Feb 25, 2026 HOLD Buy
+4.7% avg upside
23 analysts
 — -6.3%
TSE:SWA
Sarama Resources
 Apr 05, 2024 HOLD Hold
1 analyst
 — ·
GMED
Globus Medical
 May 05, 2021 BUY Strong Buy
+26.0% avg upside
24 analysts
$82.00
8.78% Upside
 -8.3%
SIBN
SI-Bone
 Mar 18, 2020 BUY Strong Buy
+64.0% avg upside
18 analysts
$27.00
77.47% Upside
 +298.9%
MDXG
MiMedx Group
 Dec 06, 2018 HOLD Strong Buy
+178.4% avg upside
17 analysts
 — +517.5%
SINT
Sintx Technologies
 Nov 11, 2016 BUY Buy
+285.0% avg upside
8 analysts
 — -59.4%
ADMA
ADMA Biologics
 Nov 06, 2015 BUY Strong Buy
+55.3% avg upside
15 analysts
$1.00
88.16% Downside
 -43.5%
ISRG
Intuitive Surgical
 Apr 19, 2013 BUY Strong Buy
+30.5% avg upside
36 analysts
$636.00
58.18% Upside
 -15.0%
OFIX
Orthofix Medical
 Apr 17, 2009 SELL Strong Buy
+214.2% avg upside
15 analysts
 — -115.2%
🔒 29 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Michael Matson — Frequently Asked Questions
How accurate are Michael Matson's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Michael's ratings were profitable over a one-year hold, with an average return of +14.7% per rating, or +7.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Michael ranked on 13Foresight?
Michael Matson is currently ranked #1891 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Michael cover?
Michael most recently has ratings on MDT, TMDX, VCYT, ICUI, BSX, ENOV, RMD, LUCD, IMDX, STE, AORT, PSNL and 22 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.